Postinfarction metoprolol treatment: effects on prognosis in relation to serum cholesterol concentrations.
In a double-blind randomized study of 154 postmyocardial infarction patients assigned to metoprolol (100 mg twice daily) and 147 patients assigned placebo, the outcome during a 3-year follow-up according to serum cholesterol concentrations was evaluated. There was no indication that metoprolol influenced the total serum cholesterol concentration. The median cholesterol value at 3 months was 6.7 mmol/l. In patients with cholesterol less than or equal to 6.7 mmol/l, nonfatal reinfarctions were reduced in the metoprolol group (7 vs. 24%; p less than 0.01). In patients with cholesterol greater than 6.7 mmol/l, mortality was lower in those treated with metoprolol (8 vs. 20%; p less than 0.05). The beneficial effect of conventional postinfarction beta-blockade with metoprolol is independent of serum cholesterol concentration.
Olsson
G
G
Department of Medicine, Karolinska Institutet, Danderyd Hospital, Sweden.
Rehnqvist
N
N
D002784:Cholesterol / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000009:adverse effects / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D010919:Placebos; D011379:Prognosis; D011897:Random Allocation; D012008:Recurrence
D010919:Placebos; D002784:Cholesterol; D008790:Metoprolol